Achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab: two case reports

In AP syndrome (APS) with severe thrombocytopenia, rituximab represents a unique drug which can balance the effect of bleeding and thrombosis. By reducing the production of autoantibodies, rituximab can simultaneously raise the platelets and reduce the chance of thrombosis by suppressing APL antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Gamoudi, Donia, Cutajar, Melanie, Gamoudi, Nadia, Camilleri, David James, Gatt, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458029/
https://www.ncbi.nlm.nih.gov/pubmed/28588823
http://dx.doi.org/10.1002/ccr3.946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458029/
https://www.ncbi.nlm.nih.gov/pubmed/28588823
http://dx.doi.org/10.1002/ccr3.946

Ejemplares similares